Example: Heart Attack

Search clinical trials for: Erlotinib

Total 686 results

NCT02194738

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Conditions: Lung Adenocarcinoma, Lung Large Cell Carcinoma, Resectable Lung Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Squamous Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage II Lung Squamous Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Squamous Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Squamous Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
NCT01130519

Active, not recruiting

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Conditions: HLRCC, Sporadic Papillary Renal Cell Cancer
NCT01013649

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
NCT01708954

Active, not recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
NCT01660971

Active, not recruiting

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
NCT02352948

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Conditions: Non - Small Cell Lung Cancer NSCLC
NCT00600496

Active, not recruiting

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
NCT03498521

Recruiting

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Conditions: Cancer of Unknown Primary Site
NCT03137771

Recruiting

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
NCT02193282

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
NCT02273362

Active, not recruiting

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Conditions: Cirrhosis, Hepatocellular Carcinoma
NCT00045201

Active, not recruiting

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Conditions: Adult Solid Neoplasm
NCT01180959

Completed

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Conditions: Liver Cancer
NCT01859026

Active, not recruiting

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
NCT01199068

Completed

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung
NCT00452413

Completed

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Conditions: Non-Small Cell Lung Cancer, Malignant Solid Tumor
NCT04591431

Recruiting

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
NCT02574078

Completed

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Conditions: Non-Small Cell Lung Cancer
NCT01210911

Completed

Metformin Combined With Chemotherapy for Pancreatic Cancer

Conditions: Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
NCT01636908

Completed

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Conditions: Cancer, Advanced Solid Tumors
NCT02091141

Active, not recruiting

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Conditions: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
NCT01562028

Completed

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Conditions: Lung Cancer
NCT02411448

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Conditions: Metastatic Non-Small Cell Lung Cancer
NCT02714530

Terminated

Thoracal Radiotherapy and Tarceva

Conditions: Cancer
NCT01306045

Active, not recruiting

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic